将雄激素受体通过转基因方式导入雌激素受体、孕激素受体及雄激素受体均呈阴性的乳腺癌细胞后，这些细胞对激素调控产生了反应。

Transgenic introduction of androgen receptor into estrogen-receptor-, progesterone-receptor-, and androgen-receptor-negative breast cancer cells renders them responsive to hormonal manipulation.

作者信息

Garreau Jennifer R, Muller Patrick, Pommier Rodney, Pommier Suellen

机构信息

Division of Surgical Oncology, Department of Surgery, Oregon Health and Sciences University, 3181 S. W. Sam Jackson Park Rd., L223A, Portland, OR 97201, USA.

出版信息

Am J Surg. 2006 May;191(5):576-80. doi: 10.1016/j.amjsurg.2006.02.004.

DOI:10.1016/j.amjsurg.2006.02.004

PMID:16647340

Abstract

BACKGROUND

Estrogen-receptor (ER)-, progesterone-receptor (PR)-, and androgen-receptor (AR)-negative breast cancer cells are unaffected by treatment with dehydroepiandrosterone-sulfate (DHEAS) and an aromatase inhibitor (AI). We hypothesized that cell growth would be inhibited with DHEAS/AI treatment after successful transfection of an AR expression vector.

METHODS

ER/PR/AR-negative breast cancer cells were transfected with an AR expression vector and treated with DHEAS/AI for 2 days. Growth inhibition of these cells was compared with that of transfected cells treated with only AI or with nontransfected cells treated with DHEAS/AI. Mann-Whitney U test was used to determine statistical significance.

RESULTS

Cell death rates of 53.5% (P = .001) and 40.1% (P = .006) were seen in transfected cells treated with DHEAS/AI compared with controls for days 1 and 2, respectively. Nontransfected cells were unaffected by treatment.

COMMENTS

ER/PR/AR-negative cells transfected with AR were killed by DHEAS/AI treatment, providing evidence that AR is responsible for this effect. This provides the first AR-targeted hormonal therapy for ER breast cancer.

摘要